Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Financing Activities (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Cash from Financing Activities for 15 consecutive years, with $267000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 49.24% to $267000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $745000.0 through Dec 2025, down 18.67% year-over-year, with the annual reading at $745000.0 for FY2025, 18.67% down from the prior year.
  • Cash from Financing Activities hit $267000.0 in Q4 2025 for Guided Therapeutics, up from $181000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $2.9 million in Q3 2022 to a low of -$154000.0 in Q3 2023.
  • Historically, Cash from Financing Activities has averaged $346600.0 across 5 years, with a median of $188500.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: surged 687.88% in 2022 and later plummeted 300.0% in 2024.
  • Year by year, Cash from Financing Activities stood at -$53000.0 in 2021, then rose by 20.75% to -$42000.0 in 2022, then surged by 566.67% to $196000.0 in 2023, then skyrocketed by 168.37% to $526000.0 in 2024, then plummeted by 49.24% to $267000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for GTHP at $267000.0 in Q4 2025, $181000.0 in Q3 2025, and $239000.0 in Q2 2025.